AMGEN Inc
NASDAQ: AMGN
$337.38
+$1.43 (+0.4%)
Closing Price on September 20, 2024
AMGN Articles
The April 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in May.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Published:
Last Updated:
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
Published:
Last Updated:
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big...
Published:
Last Updated:
These five stocks come with upward earnings revisions and the potential for rising dividends. They all make good sense for investors looking for stocks ideas as we get closer to the second quarter.
Published:
Last Updated:
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Amgen, Boeing, Chevron, Exxon Mobil, Foot Locker, Lowe's, Nokia, PayPal, Sprint and Wells Fargo.
Published:
Last Updated: